drugset / Trial / NCT02117687

A Safety and Efficacy Study of OPTIVE FUSION™ With VISMED® Multi for the Management of Dry Eye

NCT02117687

Phase 4 Completed 80 enrolled Allergan
RandomizedParallel-groupSingle-blindTreatment

Summary

This study will evaluate the safety and efficacy of OPTIVE FUSION™ compared to VISMED® Multi for the management of dry eye.

Timeline

Start
2014-05-14
Primary completion
2015-01-27
Completion
2015-03-17

Drugs

EvaluationDrugModalityDoseRoute
Comparator Carboxymethylcellulose Other / unclassified 0.5 % Other
Comparator Glycerin Other / unclassified 0.9 % Other
Comparator Sodium Hyaluronate Other / unclassified 0.18 % Other

Indications